Mediation app Headspace confirms purchase of voice-enabled AI system Alpine.AI
The mindfulness meditation app maker, Headspace, has confirmed it is set to purchase voice-enabled AI system Alpine.AI to accelerate its development in personalisation and conversational products, Mobi Health News reports.
Details of the cost of the total deal are currently undisclosed, however, it has been confirmed the Alpine team will join Headspace’s San Francisco office.
In an email to Mobi Health News, Paddy Hannon, chief technology officer at Headspace, said: “Alpine.AI will help dramatically improve our voice platforms allowing users to have a more natural conversation with our products via voice assistants like Google Home or Alexa.”
“For customers wanting to experience Headspace without their phone, and the myriad distractions that come with it, Alpine will help us ensure they have an amazing experience. We see this system evolving and we see the underlying conversational technology as critical to building a comprehensive guide to health and happiness.”
- Bayer announces rise in group sales for Q2 but warns of lower full-year earnings than expected
- Peerfit confirms $8mn in funding for its digital fitness benefits platform
- Pfizer anticipates cost of preparing for impending Brexit could hit $100mn
- Read the latest issue of Healthcare Global here!
Alpine.AI’s technology is currently being utilised into Amazon Alexa and Google Assistant with the firm aiming to provide its users the ability to communicate with their meditation services via voice technology.
In a statement, Adam Marchick, Alpine.AI CEO, said: “We are thrilled to be joining forces with the Headspace team as we see a huge opportunity to make meditation and mindfulness more accessible and the conversation natural.”
“Ultimately, this will benefit the millions of people already using Headspace and the hundreds of millions more that Headspace will impact.”
Headspace anticipates its meditation app to be part of a number of products that will be FDA approved and clinically validated with the firm hoping to utilise the products to treat a range of chronic diseases.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”